Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 | 2014-03-31 | 2013-03-31 | 2012-03-31 | 2011-03-31 | 2010-03-31 | 2009-03-31 | 2008-03-31 | 2007-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $6.0B | $5.9B | $5.5B | $5.1B | $4.5B | $4.2B | $3.1B | $3.0B | $2.8B | $2.6B | $2.6B | $2.2B | $1.9B | $1.6B | $1.5B | $1.4B | $1.2B | $1.3B | $1.3B | $1.3B | $1.2B |
| Bruttoergebnis | $2.7B | $2.6B | $2.4B | $2.2B | $2.0B | $1.9B | $1.3B | $1.3B | $1.2B | $1.1B | $1.0B | $895M | $774M | $650M | $621M | $568M | $446M | $539M | $527M | $524M | $505M |
| Bruttomarge % | 44.4% | 44.2% | 44.0% | 43.2% | 43.7% | 44.6% | 43.2% | 43.5% | 42.2% | 41.7% | 39.3% | 40.0% | 41.9% | 40.0% | 41.4% | 40.4% | 37.0% | 42.9% | 40.6% | 41.4% | 42.2% |
| Betriebsergebnis (EBIT) | $1.1B | $1.1B | $867M | $836M | $791M | $478M | $548M | $537M | $411M | $400M | $226M | $213M | $227M | $207M | $243M | $222M | $85M | $204M | $175M | $124M | $138M |
| Operative Marge % | 18.9% | 18.6% | 15.9% | 16.3% | 17.4% | 11.3% | 17.6% | 17.7% | 14.8% | 15.3% | 8.7% | 9.5% | 12.3% | 12.8% | 16.2% | 15.8% | 7.1% | 16.2% | 13.5% | 9.8% | 11.5% |
| Jahresüberschuss | $805M | $785M | $615M | $378M | $107M | $244M | $397M | $408M | $304M | $291M | $110M | $111M | $135M | $129M | $160M | $136M | $51M | $128M | $111M | $77M | $82M |
| Nettomarge % | 13.3% | 13.2% | 11.3% | 7.4% | 2.4% | 5.8% | 12.8% | 13.5% | 10.9% | 11.1% | 4.2% | 5.0% | 7.3% | 8.0% | 10.7% | 9.7% | 4.2% | 10.2% | 8.5% | 6.1% | 6.9% |
| EBITDA | — | $1.6B | $1.4B | $1.4B | $1.2B | $1.0B | $774M | $736M | $640M | $584M | $417M | $358M | $320M | $283M | $312M | $286M | $140M | $261M | $236M | $202M | $205M |
| Ergebnis je Aktie (EPS) | $8.17 | $7.95 | $6.20 | $3.81 | $1.07 | $2.48 | $4.63 | $4.76 | $3.56 | $3.39 | $1.28 | $1.56 | $2.25 | $2.17 | $2.72 | $2.31 | $0.85 | $2.16 | $1.86 | $1.20 | $1.25 |
| Ausstehende Aktien (Mio.) | — | 99M | 99M | 99M | 100M | 98M | 86M | 86M | 85M | 86M | 86M | 71M | 60M | 60M | 59M | 59M | 60M | 59M | 59M | 64M | 66M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für STE. /companies/us/STE
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms